Overview

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Stanford University
Treatments:
toripalimab